RxDoctor Payments Data

Sana Pathan, MD

Internal Medicine · Decatur, GANPI 1699205443

Payments from drug & device makers

$1,297in general payments, 2019–2025

Across 59 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$256
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$173
  • Bausch Health US, LLC$149
  • Lilly USA, LLC$146
  • Novo Nordisk$104
  • Biohaven Pharmaceuticals, Inc.$104
  • plus $364 from 11 others

What the payments were for

  • Food & beverage$1,297100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,297 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$28,393
Medicare patients
161
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$39,754
EliquisApixaban24$25,467
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,356
SymbicortBudesonide/Formoterol Fumarate13$4,722
Arnuity ElliptaFluticasone Furoate11$2,714
Albuterol Sulfate HfaAlbuterol Sulfate51$2,058
Atorvastatin Calcium87$677
Diclofenac Sodium28$535
Losartan Potassium54$528
Gabapentin58$475
Fluticasone Propionate46$442
Amlodipine Besylate113$434
Rosuvastatin Calcium40$427
Nifedipine ErNifedipine12$358
Metoprolol Succinate25$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$39,75422 claims
AstraZenecaSymbicort$29$4,72213 claims
GSKArnuity Ellipta$23$2,71411 claims
Almatica Pharma LLCSertraline Hcl$13$5013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →